Gain Therapeutics, (id:6902 GANX)

1.72 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:41:58 AM)

Exchange closed, opens in 1 day 8 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Gain Therapeutics,

Market Capitalization 43.15M

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.